Upcoming event

Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial

European Urology

Fruits, vegetables, and bladder cancer risk: A systematic review and meta-analysis

Cancer Med. , Volume 4, Issue 1, January 2015, Pages 136-146

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer

European Urology, Volume 66, Issue 6, December 2014, Pages 1148-1156

Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy

J Urol., Volume 196, Issue 6, December 2016, Pages 1627-1633

Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy

J Clin Oncol 35 (Suppl 6S; abstract 281)

Effect of contrast media on urinary cytopathology specimens

Can Urol Assoc J., August 2016, Pages 228-233

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study

J Urol. , June 2017

Therapeutic Options in High-risk Non–muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin

European Urology, Volume 67, Issue 3, March 2015, Pages 359-360

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233

J Clin Oncol. 2014 Dec 01, Volume 32, Issue 34, Pages 3801-3809

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

J Clin Oncol. 2014 Jun 20, Volume 32, Issue 18, Pages 1895-1901

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Lancet Oncol. , Volume 16, Issue 1, January 2015, Pages 76-86

FDG PET-CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy

Ann Surg Oncol. 2015 Jan 30

Previous